In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 683 ( 2023-02-15)
Abstract:
SARS-CoV-2 vaccines have been essential in combating the ongoing COVID-19 pandemic, but room for improvement remains. Here, Carreño et al . analyzed immune responses in individuals vaccinated with a Newcastle disease virus-based SARS-CoV-2 vaccine, NDV-HXP-S. This vaccine can be produced in embryonated chicken eggs, similar to the majority of influenza vaccines, making it readily translatable. The authors found that vaccination with NDV-HXP-S elicited a higher proportion of neutralizing antibodies against SARS-CoV-2 than vaccination with the BNT162b2 mRNA vaccine. NDV-HXP-S vaccinees also had a response more focused on the receptor binding domain. Together, these data highlight the promise of NDV-HXP-S, which has moved into a Phase III trial in Thailand. —CM
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abo2847
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023